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Bleeding complications after systematic switch of routine
thromboprophylaxis for major orthopaedic surgery
Abstract
The rate of bleeding complications after major orthopedic surgery approximates 2%. It is unclear
whether a systematic switch of routine thromboprophylaxis has an impact on the rate of postoperative
bleeding complications. We analyzed prospectively recorded postoperative bleeding complications and
symptomatic venous thromboembolic events in 8,176 consecutive orthopedic patients at the Schulthess
Clinic Zurich during a systematic switch of thromboprophylaxis from nadroparin to enoxaparin in the
year 2004. Overall, 3,893 patients received nadroparin in the first nine-month observation period before
the switch and 4,283 patients received enoxaparin in the second nine-month observation period after the
switch. Overall, 96 (2.5%) patients in the first period and 70 (1.6%) patients in the second period
suffered a postoperative bleeding complication requiring surgical revision, puncture, or transfusion (p <
0.01). Five objectively confirmed symptomatic venous thromboembolic events during hospitalization in
the first period and three events in the second period were recorded. In conclusion, the switch of
thromboprophylaxis in a large orthopedic clinic did not cause an increase of postoperative bleeding
complications and therefore was accompanied by high patient safety.
© 2008 Schattauer GmbH, Stuttgart
1049
Bleeding complications after systematic switch of routine 
thromboprophylaxis for major orthopaedic surgery 
Urs Kistler1, Inès Kramers-de Quervain2, Urs Munzinger3, Nils Kucher4 
1Division of Orthopedic Surgery, District Hospital Baden, Baden, Switzerland; 2Department of Rheumatology, Schulthess Clinic Zurich, 
Zurich, Switzerland; 3Department of Orthopedic Surgery, Schulthess Clinic Zurich, Zurich, Switzerland; 4Cardiovascular Center, University 
Hospital Zurich, Zurich, Switzerland 
Summary 
The rate of bleeding complications after major orthopedic sur-
gery approximates 2%. It is unclear whether a systematic switch 
of routine thromboprophylaxis has an impact on the rate of 
postoperative bleeding complications. We analyzed prospec-
tively recorded postoperative bleeding complications and symp-
tomatic venous thromboembolic events in 8,176 consecutive 
orthopedic patients at the Schulthess Clinic Zurich during a sys-
tematic switch of thromboprophylaxis from nadroparin to en-
oxaparin in the year 2004. Overall, 3,893 patients received na-
droparin in the first nine-month observation period before the 
switch and 4,283 patients received enoxaparin in the second 
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nine-month observation period after the switch. Overall, 96 
(2.5%) patients in the first period and 70 (1.6%) patients in the 
second period suffered a postoperative bleeding complication 
requiring surgical revision, puncture, or transfusion (p<0.01). 
Five objectively confirmed symptomatic venous thromboem-
bolic events during hospitalization in the first period and three 
events in the second period were recorded. In conclusion, the 
switch of thromboprophylaxis in a large orthopedic clinic did 
not cause an increase of postoperative bleeding complications 
and therefore was accompanied by high patient safety. 
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Introduction 
The efficacy and safety of systematic thromboprophylaxis after 
major orthopedic surgery has been extensively studied within the 
last 25 years. The incidence of objectively confirmed deep vein 
thrombosis (DVT) after major orthopedic surgery without pro-
phylaxis ranges between 40 and 60% (1–3). Up to one third of 
these events are symptomatic proximal DVT with an increased 
risk of acute pulmonary embolism (PE) (4–6). Randomized con-
trolled trials confirmed that thromboprophylaxis with low-mo-
lecular-weight heparins (LMWH) substantially reduces the rate 
of DVT and PE (7–9). The rate of bleeding complications after 
major orthopedic surgery with thromboprophylaxis approxi-
mates 2% (10). However, because of the different pharmacody-
namic properties, LMWH are not interchangeable for the various 
indications. Unfortunately, no head-to-head comparisons of the 
various LMWH for efficacy and safety after major orthopedic 
surgery are available.  
Many health-care professionals have direct contact with 
thromboprophylaxis in daily clinical practice. A systematic 
change in the routine use of thromboprophylaxis may potentially 
be associated with an increased risk of thrombotic and bleeding 
events. In particular, it remains unclear whether a systematic 
switch of thromboprophylaxis impacts on bleeding compli-
cations after major orthopedic surgery. 
Methods 
Patient population 
In 2004, the Schulthess Clinic Zurich, Switzerland, performed a 
switch of systematic thromboprophylaxis from nadroparin to enox-
aparin for major orthopaedic surgery. All patients with major ortho-
paedic surgery were prospectively evaluated for the occurrence of 
postoperative bleeding complications and symptomatic venous 
thromboembolic events during the hospital stay. Data acquisition 
and entry into the critical incidence reporting system (CIRS) data 
base using information from patient charts was performed by Inter-
national Classification of Diseases (ICD) coding officers. 
Nadroparin (Fraxiparine®) was routinely used until April 30, 
2004 and the switch date was May 1, 2004 when enoxaparin 
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(Clexane®) was introduced for routine thromboprophylaxis. In 
the first nine-month observation period prior to the switch (June 
1, 2003 to February 28, 2004), 3,893 patients were treated with 
nadroparin. In the second nine-month observation period after 
the switch (June 1, 2004 to February 28, 2005), 4,283 patients 
were treated with enoxaparin. The dosing regimens of both drugs 
are shown in Table 1. Nadroparin was administered in a weight-
adjusted dose, and enoxaparin was administered in a fixed dose 
of 40 mg per day. The enoxaparin dose was reduced to 20 mg per 
day in patients with a body weight of less than 50 kg, in patients 
with severe renal dysfunction (creatinin-clearance < 30 ml/min), 
and in patients who underwent surgical procedures that in-
creased the risk of bleeding complications according to the or-
thopaedic surgeon in charge. The weight-adjusted dose of nadro-
parin was reduced during the first three postoperative days. The 
timing of the first postoperative dose of thromboprophylaxis was 
not pre-specified for the first observation period. It was recom-
mended to administer the first postoperative dose of thrombo-
Table 1: Dosing schemes of the Schulthess Clinic Zurich for 
thromboprophylaxis for major orthopaedic surgery.  
Fraxiparine® (nadroparin): daily dose 
Body weight (kg) Before surgery up to 
3rd day after surgery 
Since 4th day after  
surgery 
≤ 50 1900 U.I. anti-Xa 2850 U.I. anti- Xa 
(0,2 ml) (0,3 ml) 
51–70 2850 U.I. anti-Xa 3800 U.I. anti-Xa 
(0,3 ml) (0,4 ml) 
71–95 3800 U.I. anti-Xa 5700 U.I. anti-Xa 
(0,4 ml) (0,6 ml) 
No specific recommendation was provided for the timing of the first post-
operative dose. 
Clexane® (enoxaparin) 
Standard dose 40 mg once daily before and after surgery. Patients with severe 
renal failure (Creatinin clearance < 30 ml/Min), body weight < 50 kg or with 
high bleeding risk receive enoxaparin 20 mg once daily. The first postoper-
ative dose should be administered 8 hours after surgery. 
 
 
 
 
 
 
 
 
 
 
Surgery 1. Period 2. Period P* 
N % N % 
Total 3893 100.0 4283 100.0  
Hip 0563 014.5 0663 015.5 0.204 
Knee 0723 018.6 0781 018.2 0.710 
Spine  0817 021.0 0715 016.7 < 0.001 
Shoulder 0599 015.4 0679 015.9 0.563 
Upper extremity 0391 010.0 0354 008.3 0.006 
Foot 0472 012.1 0570 013.3 0.111 
Others 0328 008.4 0521 012.2 < 0.001 
*Level of significance corrected for multiple testing: P = 0.043. 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Type of surgery in both treatment periods. 
Figure 1: Bleeding complications and symptomatic venous 
thromboembolism in both treatment periods. 
prophylaxis not earlier than eight hours after surgery in the sec-
ond observation period. Patients without thromboprophylaxis or 
those with thromboprophylaxis medications other than nadropa-
rin or enoxaparin were excluded from the analysis. There were no 
differences in surgical techniques or transfusion regulations be-
tween the two observation periodes. 
Clinical endpoints 
We analyzed in-hospital events of postoperative bleeding com-
plications and symptomatic venous thromboembolism using the 
CIRS database of the Schulthess Clinic Zurich. The following 
two predefined bleeding complications were captured: i) local 
haematoma requiring surgical revision or puncture or anemia 
necessitating transfusion of at least one unit of packed red blood 
cells; ii) local haematomas not requiring revision were not in-
cluded. Symptomatic thromboembolic events including DVT 
and PE were evaluated if the diagnosis was objectively confirm-
ed by an imaging test.  
Statistical analysis 
Sample size calculation was based on the following assump-
tions: an overall rate of bleeding complications of 2% (10); an in-
crease or decrease in bleeding complications of 1% within the 
two observation periods was defined as non-inferiority margin. 
With an alpha of 5% and a power of 90%, the sample size was 
then calculated at 3,358 patients prior to the switch date of 
thromboprophylaxis and 3,358 patients after the switch date.  
The number of orthopaedic surgical procedures and the number 
of bleeding complications in the two observation periods were 
compared with the Fisher´s exact test, respectively. The level of sig-
nificance was adjusted using Bonferroni´s correction for multiple 
comparisons (11). The effect of the enoxaparin dose on the rate of 
bleeding complications was analyzed using the chi2-test. All ana-
lyses were performed with the statistical software SPSS V15.01. 
The study was approved by the local ethics committee.  
Results 
In both observation periods, the average mean age was 56 years. 
Knee surgery, shoulder surgery, and hip surgery were performed 
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similarly often in both observation periods (Table 2). However, 
the number of patients receiving thromboprophylaxis after spi-
nal surgery and upper extremity operations was lower in the sec-
ond observation period. The mean length of hospitalization was 
8.3 ± 0.2 days in the first observation period and 8.3 ± 0.1 days 
in the second observation period. 
Overall, there were 166 (2%) postoperative bleeding compli-
cations in the two observation periods during the hospital stay: 
96 (2.5%) patients in the first and 70 (1.6%) patients in the sec-
ond observation period suffered a bleeding complication 
(p<0.01, Fig. 1). The number of bleeding complications accord-
ing to the type of surgery is shown in Table 3. In the second ob-
servation period, there appeared to be fewer bleeding compli-
cations after hip and knee surgery. The numbers of bleeding 
complications according to drug doses are summarized in Table 
4. There was no difference in bleeding complications for patients 
having received the 20-mg or the 40-mg enoxaparin dose. In pa-
tients with postoperative bleeding complications from the first 
observation period, the mean time between the end of surgery 
and the first postoperative thromboprophylaxis dose was four 
hours, and it was eight hours in patients with bleeding compli-
cations from the second observation period. 
Four in-hospital events of symptomatic DVT and one event 
of acute PE were diagnosed in the first observation period; three 
events of symptomatic DVT and no events of PE were detected in 
the second observation period. 
Discussion 
Our analysis of 8,176 patients confirmed that the switch of rou-
tine thromboprophylaxis for major orthopaedic surgery at the 
Schulthess Clinic Zurich did not cause an increase in bleeding 
complications and therefore was associated with high patient 
safety.  
The overall bleeding rate of 2% after major orthopaedic sur-
gery is comparable with the clinical outcome of large random-
ized trials (10). The rate of symptomatic DVT and PE during the 
hospitalization was even lower than expected, confirming the 
high efficacy of thromboprophylaxis with LMWH in daily clini-
cal practice.  
As expected, bleeding complications occurred more often 
after hip (4.2%) or knee arthroplasty (5.1%) than with the other 
orthopaedic surgery types (Table 3). Although the number of pa-
tients with thromboprophylaxis after spine and upper extremity 
operations was lower in the second observation period, it prob-
ably did not affect the validity of the results because the rates of 
bleeding complications after these procedures were similar in 
both observation periods.  
The present analysis has several limitations. The study was 
conducted in only one center, thus, the results may not necess-
arily be applicable to other institutions. Although data were cap-
tured systematically and prospectively, the analysis was retro-
spective, and no adjudication of the bleeding complications and 
thromboembolic events was possible. We were not able to di-
rectly compare the results of our study with other clinical prac-
tices because we did not collect data about patient comorbidities. 
According to international consensus guidelines, a prede-
fined time interval of eight hours was introduced for the first 
postoperative thromboprophylaxis dose in the second observa-
tion period (12). However, the timing of the first postoperative 
dose of thromboprophylaxis was not pre-specified for the first 
observation period, and we observed a mean time of four hours 
after surgery in patients who suffered a bleeding complication in 
the first observation period. The latter point could in part explain 
the higher bleeding rate seen in the first observation period. 
Since the time interval between the end of surgery and the first 
postoperative dose in patients without a bleeding complication 
from the first observation period was not available, we were not 
able to further investigate the effect of the timing of the first dose 
on the occurrence of bleeding complications. In addition, the en-
oxaparin dose was reduced to 20 mg per day in 16.3% of patients, 
including those patients who underwent surgical procedures 
with increased risk of bleeding. However, there was no differ-
ence in bleeding complications between the patients who receiv-
ed the 20-mg and the 40-mg enoxaparin dose. No such dosing 
precautions were recommended during the first observation 
period for nadroparin, and this could also have contributed to a 
Table 3: Bleeding complications in relation to type of surgery in 
both treatment periods. 
Table 4: Bleeding complications in relation to medication dose 
in both treatment periods.  
Surgery 1. Period 2. Period 1.+2. Period 
Bleeding % Bleeding % Bleeding % 
Total 96 2.5 70 1.6 166 2.0 
Knee 45 6.2 32 4.1 77 5.1 
Hip 30 5.3 21 3.2 51 4.2 
Spine  16 2.0 15 2.1 31 2.0 
Shoulder 03 0.5 01 0.1 04 0.3 
Upper  
extremity 
01 0.3 01 0.3 02 0.3 
Foot 01 0.2 00 0.0 01 0.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substance Operation Bleeding 
N % N % 
Total Nadroparin 3893 100.0 96 02.5 
Nadroparin 0.2 ml 0100 002.6 05 05.0 
Nadroparin 0.3 ml 1160 029.8 15 01.3 
Nadroparin 0.4 ml 1682 043.2 49 02.9 
Nadroparin 0.6 ml 0813 020.9 22 02.7 
Nadroparin 0.8 ml 0121 003.1 03 02.5 
Nadroparin 1.0 ml 0017 000.4 02 11.8 
Total Enoxaparin 4283 100.0 70 01.6 
Enoxaparin 20 mg 0696 016.3 09 01.3* 
Enoxaparin 40 mg 3587 083.7 61 01.7* 
*P-value for dose dependence of the observed bleeding rate: P = 0.438. 
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higher bleeding rate in the first observation period. It is impor-
tant to note that not only the drug choice but also other factors 
may affect the efficacy and safety of thromboprophylaxis. The 
switch of thromboprophylaxis in the Schulthess Clinic Zurich 
was accompanied by hospital-specific guidelines and training of 
the involved health care professionals. These additional factors 
may have contributed to the low bleeding rate seen in the second 
observation period. Another limitation is that bleeding compli-
cations without puncture or surgical revision but with potential 
prolongation of the patient rehabilitation were not recorded. This 
was the subjective perception of the surgeons in charge during 
the second observation period, which, however, was not reflected 
by the number of severe bleeding complications. 
In the present study, only symptomatic venous thromboem-
bolic events were recorded for the index hospital stay. However, 
postoperative DVT or PE may occur up to 90 days post surgery, 
and therefore, we probably have missed several thrombotic 
events that the patients experienced after discharge and that 
could reasonably be attributed to their previous orthopaedic sur-
gery (1, 13). This may explain the substantially lower rate of ve-
nous thromboembolism in comparison to event rates from ran-
domized controlled trials with longer follow-up. Because of the 
continuing risk of venous thromboembolism, thromboprophyla-
xis for major orthopaedic surgery, especially for hip or knee re-
placement surgery, should be extended beyond the hospital stay 
up to 35 days post surgery (1). In contrast, postoperative bleeding 
complications usually occur in the first few days after surgery 
and therefore were captured completely in our analysis, owing to 
the systematic and prospective recording of all in-hospital bleed-
ing complications that necessitated intervention or blood trans-
fusion.  
In summary, the systematic switch of thromboprophylaxis 
driven by consensus guidelines and supported by staff training in 
a large orthopaedic clinic was not associated with an increase in 
postoperative bleeding complications.  
5. White RH, Romano PS, Zhou H, et al. Incidence 
and time course of thromboembolic outcomes follow-
ing total hip or knee arthroplasty. Arch Intern Med 
1998; 158: 1525–1531. 
6. Dahl OE, Caprini JA, Colwell CW, et al. Fatal vas-
cular outcomes following major orthopedic surgery. 
Thromb Haemost 2005; 93: 860–866. 
7. Freedman KB, Brookenthal KR, Fitzgerald RH, et 
al. A meta-analysis of thromboembolic prophylaxis 
following elective total hip arthroplasty. J Bone Joint 
Surg Am 2000; 82: 929–938. 
8. Westrich GH, Haas SB, Mosca P, et al. Meta-analy-
sis of thromboembolic prophylaxis after total knee 
arthroplasty. J Bone Joint Surg Br 2000; 82: 795–800. 
9. Prandoni P. Heparins and venous thromboembol-
ism: Current practice and future directions. Thromb 
Haemost 2001; 86: 488–498. 
10. Planes A, Vochelle N, Mazas F, et al. A randomized 
trial comparing unfractioned heparin with low molecu-
lar weight heparin in patients undergoing total hip re-
placement. Thromb Haemost 1998; 60: 407–410. 
11. Keppel G. Design and analysis: A researchers' 
handbook. 3rd ed. Englewood Cliffs, NJ: Prentice-
Hall, 1991. 
12. Raskob GE, Hirsch J. Controversies in timing of the 
first dose of anticoagulant prophylaxis against venous 
thromboembolism after major orthopedic surgery. 
Chest 2003; 124: 379S–385S. 
13. Schellong S, Hesseschwerdt HJ, Paar WD, et al. 
Rates of proximal deep vein thrombosis as assessed by 
compression ultrasonography in patients receiving pro-
longed thromboprophylaxis with low molecular weight 
heparin after major orthopedic surgery. Thromb Hae-
most 2005; 94: 532–536.
References 
1. The Seventh ACCP Conference on Antithrombotic 
and Thrombolytic Therapy. Chest 2004; 126: 
163S-696S. 
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention 
of venous thromboembolism. Chest 2001; 119: 
132S-175S. 
3. Anderson FA, Wheeler HB, Goldberg RJ, et al. A 
population- based perspective of the hospital incidence 
and case fatality rates of deep vein thrombosis and pul-
monary embolism: the Worcester DVT Study. Arch In-
tern Med 1991; 151: 933–938. 
4. Douketis JD, Eikelboom JW, Quinlan DJ, et al. 
Short duration prophylaxis against venous thromboem-
bolism after total hip or knee replacement: a meta-
analysis of prospective studies investigating sympto-
matic outcomes. Arch Intern Med 2002; 162: 
1465–1471. 
